Medpace Holdings, Inc.

Medpace Holdings, Inc. is a leading global contract research organization (CRO) dedicated to accelerating the development of pharmaceuticals, biotechnology products, and medical devices. The company offers a comprehensive, end-to-end suite of clinical development services, guiding clients through all phases of research, from early-stage Phase I studies to late-stage Phase IV post-market surveillance. Medpace's expertise spans a wide array of therapeutic areas, providing critical support in areas such as development plan design, regulatory affairs, project management, and clinical monitoring. Their integrated approach includes sophisticated data management and analysis, pharmacovigilance, and support for new drug application submissions, ensuring a streamlined and efficient path to market for their clients' innovations. Furthermore, Medpace provides specialized laboratory services, including bio-analytical testing, clinical human pharmacology, advanced imaging services, and electrocardiography reading, all essential components of rigorous clinical trials. By offering these integrated solutions across North America, Europe, Asia, South America, Africa, and Australia, Medpace positions itself as a vital partner for companies seeking to bring life-changing medical advancements to patients worldwide, leveraging its deep scientific knowledge and operational excellence to navigate the complex regulatory landscape.